• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Victual Avoidance

News
Poll

A 25-year-old man presents with progressive dysphagia to solids. You order an upper endoscopy. What do the results tell you?

A 25-year-old man presents with dysphagia to solids that has progressed over the past year. He now avoids breads, meats, and other foods he fears may lodge in his esophagus. Liquids present no problem. PMH includes eczema and seasonal allergies. Upper endoscopy image is shown.

 

What is your diagnosis?

A. Eosinophilic esophagitis
B. Peptic strictures
C. Gastroesophageal reflux disease
D. Primary eosinophilic gastroenteritis
Related Content
Evidence-Based Management of Papulosquamous Disorders in Primary Care / image credit ©Daniel Beckemeier/stock.adobe.com

Evidence-Based Management of Papulosquamous Disorders in Primary Care

Grace Halsey
October 7th 2025
Article

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Linda Stein Gold, MD;Sydney Jennings
August 25th 2025
Podcast

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults / image credit ©Waldenmarus/stock.adobe.com

Novartis' Oral Targeted BTKi Treatment Approved for Chronic Spontaneous Urticaria in Adults

Grace Halsey
October 2nd 2025
Article

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care / image credit ©designua/stock.adobe.com

Atopic Dermatitis: The Pipeline and Clinical Approaches That Could Transform the Standard of Care

Patient Care Editorial Staff
September 24th 2025
Article

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b RESOLVE-AD Trial / image courtesy of George Washington University School of Medicine

Investigational IL-2 Pathway Agonist Rezpegaldesleukin Shows Promise in Phase 2b REZOLVE-AD Trial

Grace Halsey
September 23rd 2025
Article

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

© 2025 MJH Life Sciences

All rights reserved.